Pnd26 Economic Burden of Huntington's Disease in Europe

Abstract

below the Italian willingness-to-pay threshold (V 50,000 per QALY). From societal perspective, total costs per patient treated with DMF (V 1.01 M) were lower than with teriflunomide (V 1.03 M). DMF was dominant because more effective in terms of QALYs and less costly. Both sensitivity analyses confirmed robustness and reliability of base-case results. Conclusions: Results of this CEA confirm that DMF may be an optimal first-line treatment for RRMS in both Italian NHS and societal perspectives.